Why Hanmi’s Deals With Genentech and Eli Lilly Matter Beyond Korea’s Drug Industry September 02, 2026 biotech drug licensing Eli Lilly Genentech Hanmi Pharmaceutical metabolic disease obesity drugs pharmaceutical industry South Korea U.S.-Korea relations +